The Chemistry Resource Laboratory is an integral part of Roswell Park's drug development program. This resource provides chemistry services (professional advice, technical assistance, chemical syntheses) to the Institute staff members in support of their efforts to develop new anti- cancer therapies and compounds for use in studies related to mode(s) of action of cancer drug(s), biotransformation, drug disposition, etc. The """"""""added value"""""""" of this resource is the unique expertise and state-of-the-art equipment that it provides to deal with all aspects of medicinal chemistry, including the synthesis of a wide and diverse array of compounds such as anti-folates, nucleotides/nucleotide, membrane-active carbohydrates, amino acid analogues, polyamines, anti-sense agents (oligomer-dye complex) porphyrins, modified monomers for modified biopolymer syntheses and reference metabolites. The functions of this CCSG shared resource are: 1) to synthesize potential anti-cancer agents, e.g., in 5-200 g quantities for extensive preclinical chemotherapy; toxicological and pharmacological studies; 2) to prepare key intermediates in 20 g-Kg quantities for the synthesis of potential anti-cancer agents by research chemists at RPCI; 3) to prepare radioactive compounds (3H and 14C labeled) for mechanism of action and drug disposition studies: 4) to synthesize reference metabolites of active compounds for characterization purposes; and 5) to synthesize individual special compounds that demonstrate interesting and/or novel biological activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-25
Application #
6324615
Study Section
Project Start
2000-06-28
Project End
2001-04-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669

Showing the most recent 10 out of 1555 publications